Bayer Yakuhin files MAA for EYLEA with MHLW in Japan
The filing of the application is supported by the results of two Phase 3 trials, VIEW 1 and VIEW 2, conducted in Europe, Japan and other countries. The
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide. Gilead is responsible to develop, manufacture and commercialize
Using Xerox’s Communication and Marketing Services, Medco provides 65 million members the ability to personalize their prescription drug management information and communication delivery channels. This multi-channel communications approach
Sherpa Clinical Packaging provides clinical trial material management services, including packaging, labeling, distribution and returns reconciliation, for pharmaceutical, biotechnology, medical device, in-vitro diagnostics and dietary supplement companies. The